Objectives To describe the real-world experience of eculizumab use in patients with
catastrophic antiphospholipid syndrome (CAPS) according to the information provided by …

Catastrophic antiphospholipid syndrome (CAPS) is a rare disorder, characterized by the
development of multiple vascular thrombosis over a short period of time, in patients with …

Complement was identified as a critical pathway for the development of obstetrical
manifestations of the antiphospholipid syndrome (APS), and its life-threatening variant …

Catastrophic antiphospholipid syndrome (CAPS) is a rare but potentially life‐threatening
condition characterized by diffuse vascular thrombosis, leading to multiple organ failure …

Catastrophic antiphospholipid syndrome (CAPS) is fatal in approximately 44% of patients in
whom the diagnosis is made, thus demonstrating the inadequacy of current medical therapy …

Catastrophic antiphospholipid syndrome (CAPS) is a rare variant that accounts for 1% of
patients with APS. Despite its low frequency, the mortality-related is very high ranging from …

Objective Catastrophic antiphospholipid syndrome (CAPS) is characterized by
histopathologic evidence of small vessel thrombosis, dysfunction of multiple organs …

Efficacy of Eculizumab in a Patient With Immunoadsorption-De... : Medicine Efficacy of
Eculizumab in a Patient With Immunoadsorption-Dependent Catastrophic Antiphospholipid …

The current recommendation for catastrophic antiphospholipid syndrome (CAPS)
management is the standard triple therapy with anticoagulation (AC), glucocorticoids (GCs) …

The catastrophic antiphospholipid syndrome (CAPS) is a life-threating variant of the
antiphospholipid syndrome characterized by the development of multiple thrombosis in a …